Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group.
Cure H, Souteyrand P, Ouabdesselam R, Roche H, Ravaud A, D'incan M, Viens P, Fargeot P, Lentz MA, Fumoleau P, Hanauske A, Chollet P. Cure H, et al. Among authors: lentz ma. Melanoma Res. 1999 Dec;9(6):607-10. doi: 10.1097/00008390-199912000-00011. Melanoma Res. 1999. PMID: 10661773 Clinical Trial.
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M. Chevallier B, et al. Among authors: lentz ma. J Clin Oncol. 1995 Feb;13(2):314-22. doi: 10.1200/JCO.1995.13.2.314. J Clin Oncol. 1995. PMID: 7844592 Clinical Trial.
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Dieras V, Chevallier B, Kerbrat P, Krakowski I, Roche H, Misset JL, Lentz MA, Azli N, Murawsky M, Riva A, Pouillart P, Fumoleau P. Dieras V, et al. Among authors: lentz ma. Br J Cancer. 1996 Aug;74(4):650-6. doi: 10.1038/bjc.1996.416. Br J Cancer. 1996. PMID: 8761385 Free PMC article. Clinical Trial.
Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
Lhommé C, Fumoleau P, Fargeot P, Krakowski Y, Dieras V, Chauvergne J, Vennin P, Rebattu P, Roche H, Misset JL, Lentz MA, Van Glabbeke M, Matthieu-Boué A, Mignard D, Chevallier B. Lhommé C, et al. Among authors: lentz ma. J Clin Oncol. 1999 Oct;17(10):3136-42. doi: 10.1200/JCO.1999.17.10.3136. J Clin Oncol. 1999. PMID: 10506610 Clinical Trial.
Phase II study of cystemustine in advanced renal cancer.
Chauvergne J, Kerbrat P, Adenis A, Chollet P, Fargeot P, Pujade-Lauraine E, Dieras V, Madelmont JC, Lentz MA, Toulouse C, et al. Chauvergne J, et al. Among authors: lentz ma. Eur J Cancer. 1995;31A(1):130-1. doi: 10.1016/0959-8049(94)00375-f. Eur J Cancer. 1995. PMID: 7695969 Clinical Trial. No abstract available.
36 results